Summary of Significant Accounting Policies (Tables)

3 Months Ended

Sep. 30, 2021

Summary of Significant Accounting Policies

Schedule of reconciliation of the cash, cash equivalents and restricted cash amounts

	September 30, 2021		September 30, 2020
Cash and cash equivalents	$	105,321	$	108,774
Restricted cash, included in other assets		5,000		—
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	110,321	$	108,774

Schedule of the Company's net sales by medical indication

	Three Months Ended
(In thousands)	September 30,
Medical Indication	2021		2020
Analgesic	$	5,314	$	3,120
Anti-Psychosis		3,715		13,028
Cardiovascular		14,100		19,714
Central Nervous System		22,785		22,525
Endocrinology		7,845		3,233
Gastrointestinal		15,240		17,100
Infectious Disease		12,515		21,932
Migraine		4,685		9,690
Respiratory/Allergy/Cough/Cold		3,114		1,426
Urinary		1,176		1,458
Other		9,176		7,634
Contract manufacturing revenue		1,860		5,619
Total net sales	$	101,525	$	126,479

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended
	September 30,
	2021		2020
Product 1	10	%	15	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended
	September 30,
	2021		2020
Customer A	30	%	26	%
Customer B	20	%	22	%
Customer C	15	%	10	%